Meeting
2020 ASCO Virtual Scientific Program
Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab.
Authors
Paola Ghione
Memorial Sloan Kettering Cancer Center, New York, NY
Paola Ghione , Erel Joffe , Nadia De Paola , Timothy Mainardi , Sarah J. Noor , Sabela Bobillo , Patricia L. Myskowski , M. Lia Palomba , Alison J. Moskowitz , Anthony R. Mato , Fushen Sha , Gottfried Von Keudell , David J. Straus , Ariela Noy , Anas Younes , Paul A. Hamlin , Renier J. Brentjens , Miguel Angel Tejedor-Alonso , Steven M. Horwitz , Andrew David Zelenetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8062)
DOI
10.1200/JCO.2020.38.15_suppl.8062
Abstract #
8062
Poster Bd #
395
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Evaluation of the novel Bruton′s tyrosine kinase (BTK) inhibitor GDC-0853 in chronic lymphocytic leukemia (CLL) with wild type or C481S mutated BTK.
First Author: Sean David Reiff
Poster
2015 ASCO Annual Meeting
Effect of CD137 stimulation on ibrutinib antagonism of GA101 dependent NK cell-mediated cytotoxicity.
First Author: Narendiran Rajasekaran
Poster
2023 ASCO Annual Meeting
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.
First Author: Loretta J. Nastoupil
Poster
2017 ASCO Quality Care Symposium
Improving hepatitis B screening prior to rituximab at a multispecialty urban hospital.
First Author: Lakshminarayanan Nandagopal